Fingerprint
Dive into the research topics of 'Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen*, Jeff P. Sharman, Yasuhiro Oki, Ranjana H. Advani, Jane N. Winter, Celeste M. Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A. Kennedy, Pamela Levine, Jing Yang, Nancy L. Bartlett
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
257
Scopus
citations